Radient Pharmaceuticals Corporation fka RXPC

[Future Doc]

Gold, I agree that the odds are difficult to overcome. As far as the normal distribution for cancer stages. I would have to assume that they would be sightly biased toward the early stages as far as CRC is concerned. This is due to the fact that CRC cases have been steadily increasing over the past 20 years. Increasing absolute value of cases means that more new cases, or early stage cancers, are occurring every year. So in a given year, a proper sample should contain more early stage cancers than late stage cancers (also due to the fact that late stage cancer patients don't live very long).